BRIEF published on 09/02/2026 at 12:35, 2 months ago Immunic to Host Virtual R&D Day on Multiple Sclerosis Biotechnology Immunic Vidofludimus Calcium Relapsing MS R&D Event
PRESS RELEASE published on 09/02/2026 at 12:30, 2 months ago Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 Immunic, Inc. to host a virtual R&D day on relapsing multiple sclerosis on September 9, 2026, discussing its Phase 3 trial asset, vidofludimus calcium, to address neurologic diseases Immunic Inc. Phase 3 Trial Vidofludimus Calcium Relapsing Multiple Sclerosis Virtual R&D Day
BRIEF published on 09/01/2026 at 12:35, 2 months 1 day ago Immunic Appoints Chitrang Davé as Chief Data and Digital Officer Multiple Sclerosis Immunic Vidofludimus Calcium Chitrang Davé Data And Digital
PRESS RELEASE published on 09/01/2026 at 12:30, 2 months 1 day ago Immunic Appoints Chitrang Davé as Chief Data and Digital Officer Immunic appoints Chitrang Davé as Chief Data and Digital Officer, reinforcing commitment to building a robust data ecosystem for potential NDA submission and commercialization Chief Data Officer Immunic Digital Officer NDA Submission Chitrang Davé
BRIEF published on 08/11/2026 at 12:35, 2 months 22 days ago Immunic, Inc. Reports Q2 2026 Financial Results and Updates Vidofludimus Calcium Leadership Appointments Multiple Sclerosis Trials Biotech Investments Immunic Financials
PRESS RELEASE published on 08/11/2026 at 12:30, 2 months 22 days ago Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. reports Q2 2026 financial results and corporate update, with leadership team expansions and Phase 3 trials progress for vidofludimus calcium in MS Financial Results Corporate Update Immunic Inc. Vidofludimus Calcium Q2 2026
BRIEF published on 08/10/2026 at 22:10, 2 months 22 days ago Elena Ridloff Joins Immunic's Board as Strategic Director Vidofludimus Calcium Immunic Board Elena Ridloff Biotechnology Leadership Phase 3 ENSURE
PRESS RELEASE published on 08/10/2026 at 22:05, 2 months 22 days ago Immunic Appoints Elena Ridloff to Board of Directors Immunic appoints Elena Ridloff, a financial and capital markets expert, to its Board of Directors, enhancing leadership as the company approaches pivotal phase 3 ENSURE Readout for Multiple Sclerosis treatments Board Of Directors Immunic Elena Ridloff MS Treatments ENSURE Readout
BRIEF published on 07/09/2026 at 12:35, 3 months 24 days ago Immunic Announces Participation in July Investor Conferences Biotechnology Investor Conferences Immunic Inc. Oral Therapies Neurologic Diseases
PRESS RELEASE published on 07/09/2026 at 12:30, 3 months 24 days ago Immunic to Participate in Investor Conferences in July Immunic, Inc. (Nasdaq: IMUX) to participate in investor conferences in July, presenting at Leerink Partners Therapeutics Forum and B. Riley Securities Mind, Muscle & Vision Summit in Boston Investor Conferences Immunic Inc B. Riley Securities Neurologic Diseases Leerink Partners
Published on 11/02/2026 at 16:15, 31 minutes ago ACCESS Newswire Launches SPOT, Seven AI Agents That Check Every Press Release Before Submission
Published on 11/02/2026 at 15:00, 1 hour 46 minutes ago CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 2 hours 46 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 2 hours 46 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 3 hours 16 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 15:58, 48 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 15:19, 1 hour 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/02/2026 at 15:19, 1 hour 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/02/2026 at 15:25, 1 hour 21 minutes ago Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026
Published on 10/30/2026 at 23:00, 2 days 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 22 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 4 hours ago Capital increase through exercise of subscription rights
